Crescent Financial Partners is in charge of B2P’s market launch product, designed for monitoring the extent to which bacteria spreads in different type of largely consumed products, such as water, dairy etc. The B2P is a clean tech company that will be featured in the December issue of Popular Science as one of the most 100 innovative companies of 2010.

The company has also tackled micro-bio-informatics technology by developing products which are able to give an efficient gauge of the safety of the water used in different purposes (drinking water, water waste, aqua-farming).

The collaboration between Crescent and B2P is based on mutuality in terms of gains: while the latter is keen to take advantage of Crescent’s experience in a successful market launch, Crescent’s aim turns into fortune with an innovative approach towards the wise use of natural resources.

Dr. Rosemary Sharpin, the founder and CEO of B2P also declared that “We realize it is imperative to have the guidance of professionals who have a track record of success when it comes to launching technology products into this part of the world – we trust the Crescent Financial Partners team and know that we have retained the best in the business.”

Crescent is also conscious of feasible technologies are in the direct spolightt of the public, and the gain in capital is worth the invested energies. The private equity merchant banking firm has a hefty portfolio, working in the past with IT Trading, an arbitrage trading system which is a quantitative trading software, as well as Genea, a software system that controls energy use in businesses.  It was named by Forbes as America’s most promising companies in 2009.

The CEO and Managing Director of Crescent Financial Partners, Russell Armstrong has mentioned that “Our goals are to bring B2P into the U.S. market and to put their disruptive technology suite in front of U.S. investors. I see their technology as a huge asset for the investment community to have in their portfolios as the issues surrounding food and water safety become more top of mind with U.S. consumers. Another reason I’m excited about this opportunity is because the economic landscape is ripe for innovations that impact the bottom line – B2P can save companies millions of dollars in the long run with their low-risk, affordable, bacterial safety testing, advanced technology.”